Traditional Chinese medicine composition for treating mosquito bites

Abstract

The invention discloses a traditional Chinese medicine composition for treating mosquito bites, which realizes the following effects by accurately controlling the molecular collision energy (E is greater than or equal to 12kJ / mo) of active ingredients such as alkannin, hydroxysafflor yellow A and the like: inhibiting histamine release (IC50 is less than or equal to 15mu M); the itching relieving time is within 25 seconds; the pH value of the skin is kept in a physiological range of 6.8-7.2; the mast cell degranulation inhibition rate is greater than or equal to 75%.

Description

Technical Field

[0001] This invention belongs to the field of traditional Chinese medicine preparation technology, specifically relating to a traditional Chinese medicine composition for treating mosquito bites, especially suitable for treating local inflammatory reactions caused by mosquito bites. Background Technology

[0002] The local inflammatory response (redness, swelling, heat, itching, and pain) caused by mosquito bites is essentially an overreaction of the immune system to foreign proteins. Current treatment options face three major technical barriers:

[0003] a) Antihistamines, taken orally, have a long journey, involve too many substances in the internal organs, and have significant side effects; b) Wind-dispelling powders, taken orally, are the same as above, but only dispel wind, induce sweating, and remove dampness, resulting in a long journey and excessive material consumption; c) External applications only increase body exudation to dilute: too much redness, swelling, and heat is consumed, and the accumulation of these substances thickens the skin surface and leads to local metabolic depression.

[0004] Commonly used antihistamines (such as loratadine) can only block H1 receptors (IC50 = 35-45 μM) and are ineffective against inflammatory mediators such as bradykinin and prostaglandins; although glucocorticoids (hydrocortisone) can inhibit IL-6 (inhibition rate 68%), the rate of epidermal atrophy increases threefold after 7 days of continuous use; calamine lotion only works through physical isolation, and itching relief takes 45-60 minutes.

[0005] The Chinese Pharmacopoeia records antipruritic formulas (such as Xiaofeng San) with excessively large dosage fluctuations (±35%); the ratio of ephedra to gypsum is recorded as 1:2-1:10 in ancient books, which lacks modern pharmacokinetic verification; the laxative component of rhubarb (sennoside) may cause damage to the stratum corneum due to local accumulation of the skin.

[0006] Commercially available gels generally have a pH value that deviates from the physiological value of the skin (pH 5.5 ± 0.5), and long-term use leads to a decrease in filaggrin expression; the transdermal absorption rate of cream matrix is ​​<2%, requiring frequent application (QID); preparations containing menthol (content >3%) may cause contact dermatitis if used continuously for more than 2 weeks.

[0007] The applicant discovered through molecular dynamics simulation (GROMACS2023.3) that when the collision energy of drug molecules E≥12kJ / mol and the collision frequency f>10^9Hz, it can induce the transient opening of calcium ion channels in skin keratinocytes (opening time>200ms), thereby reconstructing the local immune microenvironment. Summary of the Invention

[0008] This invention relates to the field of modern Chinese medicine formulation technology, specifically to a composition containing seven medicinal materials including gromwell root, gypsum, and safflower, which achieves targeted therapy by regulating the molecular collision energy of the active ingredients.

[0009] This invention provides a traditional Chinese medicine composition for treating mosquito bites, comprising, by weight: 2 parts of Lithospermum erythrorhizon root extract (shikonin ≥ 18%); 5 parts of gypsum (crystallization water ratio 85-92%); 1 part of safflower (hydroxysafflower yellow A ≥ 0.3%); 1 part of ephedra (ephedrine:pseudonym = 1:1.2-1.5); 20 parts of rhubarb (sennoside A+B ≥ 1.8%); 50 parts of immature bitter orange (synephedrine ≥ 90%); and 50 parts of burdock fruit (arbuscular inosin ≥ 6%). The composition is optimized through molecular collision theory, wherein the Lithospermum erythrorhizon root extract and burdock fruit extract form a hydrogen bond network, inhibiting mast cells. Degranulation (inhibition rate ≥75%); the golden ratio of ephedrine to pseudoephedrine (1:1.3) bidirectionally regulates the TRPV1 channel, reducing the efficiency of pruritus signal transduction by 42%; gypsum crystal water forms a dynamic hydration layer on the skin surface, maintaining local humidity at 68±2% (tested in a 25℃ / 60%RH environment), clarifying the essential technical characteristics (components + content) of the composition, covering the core innovation points of traditional Chinese medicine compound formulation; through molecular mechanism description, a correlation model between component ratio and efficacy is established to enhance patent stability; the limit requirements for gypsum crystal water in the 2020 edition of the Chinese Pharmacopoeia are cited to ensure the feasibility of the technical solution.

[0010] Furthermore, the *Lithospermum erythrorhizon* root extract was prepared using supercritical CO2 extraction at an extraction pressure of 25-30 MPa and a temperature of 45-50°C. The extraction process parameters were optimized through orthogonal experiments, specifically including: an extraction time of 3.5 hours (gradient experiments determined the optimal extraction efficiency); and a separation vessel I pressure of 8 MPa and a temperature of 40°C (increasing the purity of *Lithospermum erythrorhizon* to 92%). This parameter refinement establishes a technological barrier, preventing simple imitation; and the clearly defined critical process parameters (CPP) ensure that the *Lithospermum erythrorhizon* content remains stable at ≥18%.

[0011] Furthermore, the gypsum granules are pulverized to a D90 < 50 μm using a ball mill. The pulverization process employs a three-stage classification system: primary pulverization (coarse crushing): particle size D50 = 150 μm; secondary pulverization (medium crushing): particle size D50 = 80 μm; tertiary pulverization (fine crushing): using an air jet mill, D90 < 50 μm; ensuring that the drug dissolution rate meets the sustained-release requirements (cumulative release rate ≥ 85% over 12 hours); clearly defining the type of classification equipment (air jet mill) to avoid the ambiguity of ball mill parameters in existing technologies; micron-sized particles reduce the loss of crystal water and extend the shelf life to 24 months.

[0012] Furthermore, the safflower whole-flower extract is extracted using microwave-assisted extraction with a microwave power of 400W and an extraction time of 30 minutes. The microwave extraction employs a multi-mode resonant cavity design, with specific parameters including: pulse frequency of 2450MHz (penetration depth ≥5cm); duty cycle of 70% (to prevent thermal decomposition of active ingredients); compared to the traditional reflux method, the extraction rate of hydroxysafflower yellow pigment A is increased by 65%; the non-thermal effect of microwaves preserves volatile terpenoids (retention rate ≥90%); and the limited duty cycle prevents equipment overheating, meeting GMP requirements.

[0013] Furthermore, the ephedra extract is purified using a macroporous resin; the purification process includes: resin type: D101 styrene-divinylbenzene copolymer (specific surface area 450±50m²). 2 / g); Gradient elution program: elution flow rate 2 BV / h (dynamic adsorption capacity ≥120 mg / g); Ephedrine purity increased from 45% of crude extract to 82%; flow rate matched with resin pore size to avoid leakage; different from conventional column chromatography (yield increased by 2.3 times).

[0014] Furthermore, the raw rhubarb extract is extracted using dynamic countercurrent extraction with a material-to-liquid ratio of 1:8. The dynamic countercurrent system is configured with: a three-stage series extraction tank (temperature gradient: 60℃→70℃→80℃); a solvent circulation flow rate of 200L / h (to maintain stable extraction efficiency); online pH monitoring (control range 5.5-6.0); the extraction rate of sennoside A+B is increased from 38% in the traditional decoction method to 92%; the temperature gradient design prevents the degradation of emodin (retention rate ≥95%); and pH monitoring ensures a tannin removal rate ≥85%.

[0015] Furthermore, the *Citrus aurantium* peel extract, after freeze-drying, has a moisture content of ≤5%. The freeze-drying process parameters are: pre-freezing temperature -40℃ (ice crystal nucleation control); sublimation drying stage vacuum degree 10Pa (sublimation rate ≥5kg / m³). 2 •h); Desorption drying endpoint temperature 45℃ (synephrine retention ≥98%); Avoid high temperature to prevent synephrine oxidation (content determination RSD <1.5%); Different from conventional spray drying method (moisture content reduced from 8% to 5%); Moisture content meets the requirements of the "Standard for Quality of Solid Dosage Forms of Traditional Chinese Medicine".

[0016] Furthermore, the burdock fruit extract is extracted using enzymatic hydrolysis, with 2% cellulase added and a hydrolysis temperature of 50°C. The enzymatic hydrolysis system includes: hydrolysis buffer: pH 5.0 disodium hydrogen phosphate-citric acid buffer; coenzyme system: β-glucosidase (0.5%); reaction termination condition: boiling water bath inactivation for 10 minutes; the arctiin extraction rate is increased from 52% in the traditional water extraction method to 89%; the enzyme synergistic effect improves the yield of aglycone components; and precise temperature control prevents enzyme inactivation (activity retention rate ≥90%).

[0017] Furthermore, the excipients comprise β-cyclodextrin and magnesium stearate in a mass ratio of 1:3. The excipient system functions as follows: β-cyclodextrin encapsulates shikonin (encapsulation rate ≥85%), increasing transdermal absorption by 3.2 times; magnesium stearate acts as a lubricant (dosage ≤3%), ensuring tablet disintegration time ≤15 minutes; the combination of the two ensures a particle repose angle ≤35° (meeting flowability standards); it solves the problem of easy moisture absorption and clumping of traditional Chinese medicine powders (moisture absorption rate <2%); it differs from conventional starch excipients (disintegration speed increased by 40%); and the parameter combination ensures smooth tableting (hardness 8-10kN).

[0018] Furthermore, it is made into a liquid with an inlet air temperature of 50°C and an atomization pressure of 0.15 MPa.

[0019] The advantages of this invention are:

[0020] Compared with existing technologies, the composition of this invention achieves three major breakthrough advantages:

[0021] (1) Shikonin (2%) and arctiin (6%) form a hydrogen bond network, increasing the mast cell degranulation inhibition rate to 82% (vs. 41% with shikonin alone); the golden ratio of ephedrine (1:1.3) and pseudoephedrine can bidirectionally regulate the TRPV1 channel (activation threshold reduced by 42%); gypsum water of crystallization (85-92%) is slowly released at 32℃, maintaining local humidity at a constant 68±2%.

[0022] (2) Intelligent molecular collision regulation system

[0023]

[0024] (3) The β-cyclodextrin (1:3) inclusion technology was used to reduce the particle size of the drug molecules to 47±3nm; the dynamic countercurrent extraction process increased the transfer rate of active ingredients by 65% ​​(compared to only 42% in the traditional process); the sustained-release microcapsules achieved "two-phase release": 38% of the active ingredients were released in the first 2 hours and the steady-state concentration was maintained for the next 72 hours; acute toxicity test (LD50>5000mg / kg, mice by gavage).

[0025] (4) Skin irritation score (erythema index <0.5, edema index <0.3); no abnormal changes in liver and kidney function indicators were found after 90 days of continuous administration.

[0026] Technical Parameter Comparison Table

[0027]

[0028] [Standardization of Drug Collection] Establish a standardized collection system for seven medicinal materials: the root of Lithospermum erythrorhizon is selected from three-year-old wild varieties in Kulun Banner, Inner Mongolia (Lithospermum erythrorhizon content ≥18%), the gypsum is collected from high-quality fibrous mineral sources in Yingcheng, Hubei (crystallization water ratio 85-92%), and the safflower is selected from the first harvest of flowers in Yumin County, Xinjiang (hydroxysafflower yellow pigment A ≥0.3%). The quality of raw materials is traced throughout the entire process through fingerprinting technology.

[0029] [High-Efficiency Drug Production] Five innovative core processes: ① Supercritical extraction of shikonin yield increased to 92% (compared to only 68% by traditional ethanol extraction); ② Ephedrine / pseudonym golden ratio separation and purification efficiency increased by 3.2 times; ③ Dynamic countercurrent extraction of rhubarb sennosides reduced solvent consumption by 45%; ④ Lyophilin freeze-drying retention rate of immature bitter orange ≥98% (compared to only 82% by spray drying); ⑤ Enzymatic extraction of burdock fruit achieved an aglycone conversion rate of 89% (compared to 52% by traditional water extraction).

[0030] [Controllable Drug Costs] Cost reduction and efficiency improvement achieved through process optimization: The production cost per unit of active ingredient is reduced by 38% compared with traditional processes, including a 50% reduction in energy consumption in the ephedrine purification step and a 22% reduction in raw material loss in the gypsum ball milling and classification system.

[0031] [Drug Storage Stabilization] Innovative triple stability assurance system: ① Gypsum D90 <50μm particles reduce water of crystallization loss (24-month shelf life); ② β-cyclodextrin inclusion technology isolates oxygen (synephrine oxidation rate <1.5%); ③ pH-sensitive coating technology maintains formulation stability (active ingredient degradation rate <3% under 40℃ / RH75%).

[0032] [Precision Drug Efficacy] Constructing a multi-target synergistic network: ① The hydrogen bond network of shikonin-arbuscular inosine increases the mast cell degranulation inhibition rate to 82%; ② The golden ratio of ephedrine / pseudoephedrine bidirectionally regulates the TRPV1 channel (itch signal blocking efficiency of 42%); ③ The gypsum crystal water dynamic moisturizing system maintains the skin's physiological environment of pH 6.8-7.2.

[0033] [Elimination of Drug Odors] A three-step deodorization process is adopted: ① Ethanol distillation recovery system after ephedrine extraction removes the irritating odor; ② β-cyclodextrin encapsulation masks the special odor of synephrine; ③ 0.3% menthol microcapsules (sustain-release type) are added to the finished product to balance the drug odor. The odor elimination rate reached 91% according to the sensory evaluation team. Detailed Implementation

[0034] Example 1: Comfrey and gypsum antipruritic tablets (corresponding to claims 1-3, 9)

[0035] prescription:

[0036] Shikonin extract (2 portions, ≥18%) 40g

[0037] 100g of raw gypsum granules (5 parts, D90 < 50μm)

[0038] Safflower extract (1 part, ≥0.3%) 20g

[0039] Ephedra extract (1 part, 1:1.3) 20g

[0040] Raw rhubarb extract (20 parts, ≥1.8%) 400g

[0041] Citrus aurantium extract (50 parts, ≥90%) 1000g

[0042] Burdock seed extract (50 parts, ≥6%) 1000g

[0043] β-Cyclodextrin 60g

[0044] 20g magnesium stearate

[0045] Preparation process:

[0046] Mixing: Add the extracts of the seven medicinal herbs and β-cyclodextrin into a V-type mixer, mix at 15 r / min for 30 minutes.

[0047] Liquid preparation: Add purified water (material ratio 1:0.8) and perform a wet process to produce a liquid. Quality control:

[0048] Shikonin content: determined by HPLC (labeled amount ± 5%)

[0049] In vitro release rate: Paddle method (75 rpm, pH 6.8 medium), 38% release in 2 hours.

[0050] Example 2: Burdock and Ephedra sustained-release gel (corresponding to claims 1, 4, 7, and 8)

[0051] prescription:

[0052] Ephedra extract (1 part, 1:1.3) 20g

[0053] Burdock seed extract (50 parts, ≥6%) 1000g

[0054] Hydroxypropyl methylcellulose (HPMC K100M) 300g

[0055] 150ml of glycerin

[0056] Preparation process:

[0057] Preparation of extract: Mix ephedra extract and burdock seed enzymatic hydrolysate in a 1:3 ratio.

[0058] Gel matrix preparation: HPMC was soaked in cold water for 2 hours and swollen in a 60°C water bath.

[0059] Homogenization: Homogenize the mixture with glycerin at 10,000 rpm for 10 minutes.

[0060] Filling: The automatic filling machine dispenses the contents into aluminum tubes, 50g per tube.

[0061] Quality control:

[0062] Viscosity: Measured using an NDJ-1 rotational viscometer (25℃, 20 rpm) (2500-3500 mPa·s). In vitro release rate: ≥85% cumulative release rate over 12 hours in a Franz diffusion cell (artificial skin model). Microbial limits: ≤100 CFU / g total aerobic bacteria count according to Part IV of the Chinese Pharmacopoeia.

[0063] Example 3: Quick-release spray of Citrus aurantium and Rhubarb (corresponding to claims 1, 5, and 6)

[0064] prescription:

[0065] Citrus aurantium extract (50 parts, ≥90%) 1000g

[0066] Raw rhubarb extract (20 parts, ≥1.8%) 400g

[0067] PVP K30 200g

[0068] Preparation process:

[0069] Solution preparation: Combine the extracts of Citrus aurantium and Rheum palmatum.

[0070] Adjust pH: Adjust the pH to 6.8 using a 10% citric acid solution.

[0071] Filling: Dispensed via metered spray pump (0.1ml per spray), 1000 bottles in total.

[0072] Quality control:

[0073] Spray rate: Measured using a TSI-300 spray characteristics tester (room temperature 25℃) (0.8±0.1g / s)

[0074] Active ingredient transfer rate: determined by UV method (≥92% relative to the raw material extract).

[0075] Example 4: Safflower Gypsum Transdermal Patch (corresponding to claims 1, 2, and 4)

[0076] prescription:

[0077] Safflower extract (1 part, ≥0.3%) 20g

[0078] 100g of raw gypsum granules (5 parts, D90 < 50μm)

[0079] Pressure-sensitive adhesive (acrylate) 800g

[0080] Azone 10g

[0081] Preparation process:

[0082] Drug layer preparation: Safflower extract and gypsum granules were ultrasonically dispersed (40 kHz, 30 minutes).

[0083] Coating: A doctor blade coater (coating thickness 0.25mm) is used on the backing material.

[0084] Quality control:

[0085] Ointment content: determined by weight variation method (labeled amount ±7%)

[0086] In vitro transdermal permeability: Franz diffusion cell (ex vivo rat skin), 24-hour cumulative permeation ≥60%; Adhesion: YBB00332004-2015 standard test (initial adhesion ≥ No. 5 steel ball).

[0087] Example 5: Ephedra and Burdock Sustained-Release Microgranules (corresponding to claims 1, 5, 7, and 8)

[0088] prescription:

[0089] Ephedra extract (1 part, 1:1.3) 20g

[0090] Burdock seed extract (50 parts, ≥6%) 1000g

[0091] EC (Ethyl Cellulose) 300g

[0092] PEG6000 50g

[0093] Appropriate amount of purified water

[0094] Release rate: USP IV method (0.1 mol / L HCl 2h → pH 6.8 phosphate buffer 22h), release ≤35% in the first 2h, cumulative release ≥80% in 24h.

[0095] Content uniformity: Detected according to the method in Part IV of the Chinese Pharmacopoeia (A+2.2S≤15.0)

[0096] Morphological observation: Scanning electron microscopy (SEM) showed the sphericity of the microparticles (sphericity coefficient 0.92±0.03).

Claims

1. A traditional Chinese medicine composition for treating mosquito bites, characterized in that By mass parts comprising: Radix lithospermi extract 2 parts (shikonin ≥ 18%) Gypsum alabaster 5 parts (crystallization water ratio 85-92%) Carthamus tinctorius 1 part (hydroxysafflor yellow A ≥ 0.3%) Ephedra 1 part (ephedrine: pseudoephedrine = 1:1.2-1.5) Raw rhubarb 20 parts (sennoside A+B ≥ 1.8%) Fructus aurantii 50 parts (syringin ≥ 6%). The radix lithospermi extract is prepared by supercritical CO2 extraction method, extraction pressure 25-30 MPa, temperature 45-50℃.

2. The traditional Chinese medicine composition for treating mosquito bites according to claim 1, characterized in that: The gypsum alabaster particles are ground by a ball mill to D90 < 50μm.

3. The traditional Chinese medicine composition for treating mosquito bites according to claim 1, characterized in that: The carthamus tinctorius whole flower extract is extracted by microwave-assisted extraction, microwave power 400W, extraction time 30 minutes.

4. The traditional Chinese medicine composition for treating mosquito bites according to claim 1, characterized in that: The ephedra extract is purified by macroporous resin.

5. The traditional Chinese medicine composition for treating mosquito bites according to claim 1, characterized in that: The raw rhubarb extract is extracted by dynamic countercurrent extraction, solid-liquid ratio 1:

8.

6. The traditional Chinese medicine composition for treating mosquito bites according to claim 1, characterized in that: The fructus aurantii pericarp extract is freeze-dried, water content ≤ 5%.

7. The traditional Chinese medicine composition for treating mosquito bites according to claim 1, characterized in that: The fructus arctii fruit extract is extracted by enzyme-assisted extraction, cellulase addition amount 2%, enzymolysis temperature 50℃.

8. The traditional Chinese medicine composition for treating mosquito bites according to claim 1, characterized in that: The excipient comprises β-cyclodextrin and magnesium stearate, mass ratio 1:

3.

9. The traditional Chinese medicine composition for treating mosquito bites according to claim 1, characterized in that: Made into a liquid, air inlet temperature 50℃, atomization pressure 0.15MPa.

10. The traditional Chinese medicine composition for treating mosquito bites according to claim 1, characterized in that: ​

Images